Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease

ConclusionThe present study showed that the effects and safety of OBV/PTV/r therapy in genotype 1b chronic hepatitis C patients with non‐dialysis CKD were not inferior to those in patients without CKD.

Source: Hepatology Research - January 9, 2018 Category: Internal Medicine Authors: Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Tadashi Ikegami, Noritomo Shimada, Keizo Kato, Hiroshi Abe, Tomomi Okubo, Norio Itokawa, Chisa Kondo, Shigeru Mikami, Toru Asano, Yoshimichi Chuganji, Yasushi Matsuzaki, Hidenori Toyoda, Takashi Kumada, Ets Tags: Original Article Source Type: research